ProfileGDS5678 / 1424344_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 88% 88% 87% 90% 90% 89% 89% 89% 89% 89% 89% 89% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6823487
GSM967853U87-EV human glioblastoma xenograft - Control 26.9517188
GSM967854U87-EV human glioblastoma xenograft - Control 36.9422188
GSM967855U87-EV human glioblastoma xenograft - Control 46.929987
GSM967856U87-EV human glioblastoma xenograft - Control 57.2335390
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8929590
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8321989
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9401389
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9366789
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9936489
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9401389
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1793989
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9511189
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1126990